Optina Diagnostic Patents

Patent portfolio assigned to Optina Diagnostic (verified via public assignee records). Hyperspectral retinal imaging (MHRC) for Alzheimer's/amyloid detection (Montreal); FDA 510(k) + Breakthrough Device designation. Patents confirmed via Justia assignee page (e.g. US10964036B2, US20190150733A1). RetiSpec is a directly named competitor (same hyperspectral-retinal-Alzheimer's space). No named paying customers found (clinical/research stage).